Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Page 1
ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis.
Gilchrist FJ, Bui S, Gartner S, McColley SA, Tiddens H, Ruiz G, Stehling F, Alani M, Gurtovaya O, Bresnik M, Watkins TR, Frankovic B, Skov M; ALPINE2 study investigators. Gilchrist FJ, et al. Among authors: mccolley sa. J Cyst Fibros. 2024 Jan;23(1):80-86. doi: 10.1016/j.jcf.2023.06.008. Epub 2023 Jul 15. J Cyst Fibros. 2024. PMID: 37455237 Free article. Clinical Trial.
Both courses were well tolerated, further supporting AZLI short-term safety in paediatric and adolescent pwCF. CLINICALTRIALS: GOV: NCT03219164....
Both courses were well tolerated, further supporting AZLI short-term safety in paediatric and adolescent pwCF. CLINICALTRIALS: GOV: N …
Late Diagnosis in the Era of Universal Newborn Screening Negatively Affects Short- and Long-Term Growth and Health Outcomes in Infants with Cystic Fibrosis.
Martiniano SL, Wu R, Farrell PM, Ren CL, Sontag MK, Elbert A, McColley SA. Martiniano SL, et al. Among authors: mccolley sa. J Pediatr. 2023 Nov;262:113595. doi: 10.1016/j.jpeds.2023.113595. Epub 2023 Jul 3. J Pediatr. 2023. PMID: 37406853
Through evaluation of national patient registry data, we determined that late initiation of cystic fibrosis care is associated with poorer long-term nutritional outcomes....
Through evaluation of national patient registry data, we determined that late initiation of cystic fibrosis care is associated with poorer l …
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial.
Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH, Retsch-Bogart G, Roesch E, Ahluwalia N, Chin A, Chu C, Lu M, Menon P, Waltz D, Weinstock T, Zelazoski L, Davies JC. Wainwright C, et al. Among authors: mccolley sa. Am J Respir Crit Care Med. 2023 Jul 1;208(1):68-78. doi: 10.1164/rccm.202301-0021OC. Am J Respir Crit Care Med. 2023. PMID: 37154609
Rationale: A 24-week, phase 3, open-label study showed elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was safe and efficacious in children aged 6-11 years with cystic fibrosis (CF) and one or more F508del-CFTR alleles. Objectives: To assess long-term safety and efficacy of …
Rationale: A 24-week, phase 3, open-label study showed elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was safe and efficacious in children a …
Anti-racist strategies for clinical and translational research: Design, implementation, and lessons learned from a new course.
Heard-Garris NJ, Brown JF, Ewulonu UC, Goel MS, Gordon AS, Henley C, Khan SS, Smith SM, McColley SA. Heard-Garris NJ, et al. Among authors: mccolley sa. J Clin Transl Sci. 2022 Dec 22;7(1):e26. doi: 10.1017/cts.2022.524. eCollection 2023. J Clin Transl Sci. 2022. PMID: 36721401 Free PMC article.
A course designed to teach anti-racist research design is feasible and has a positive short-term impact on learners....
A course designed to teach anti-racist research design is feasible and has a positive short-term impact on learners....
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.
Hoppe JE, Chilvers M, Ratjen F, McNamara JJ, Owen CA, Tian S, Zahigian R, Cornell AG, McColley SA. Hoppe JE, et al. Among authors: mccolley sa. Lancet Respir Med. 2021 Sep;9(9):977-988. doi: 10.1016/S2213-2600(21)00069-2. Epub 2021 May 6. Lancet Respir Med. 2021. PMID: 33965000
BACKGROUND: A previous phase 3 study showed that lumacaftor-ivacaftor was generally safe and well tolerated over 24 weeks of treatment in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation. In this study, we aimed to assess the long-term …
BACKGROUND: A previous phase 3 study showed that lumacaftor-ivacaftor was generally safe and well tolerated over 24 weeks of treatment in ch …
Preferences for disclosing adverse childhood experiences for children and adults with cystic fibrosis.
Williams WA 2nd, Jain M, Laguna TA, McColley SA. Williams WA 2nd, et al. Among authors: mccolley sa. Pediatr Pulmonol. 2021 May;56(5):921-927. doi: 10.1002/ppul.25243. Epub 2021 Jan 12. Pediatr Pulmonol. 2021. PMID: 33369260
INTRODUCTION: The 2017-2018 National Survey of Children's Health estimates that 30 million (42%) US children have experienced at least one adverse childhood experience (ACE), including abuse, neglect, and household dysfunction. ACEs negatively impact long-term health, and …
INTRODUCTION: The 2017-2018 National Survey of Children's Health estimates that 30 million (42%) US children have experienced at least one a …
Quantity not sufficient rates and delays in sweat testing in US infants with cystic fibrosis.
McColley SA, Elbert A, Wu R, Ren CL, Sontag MK, LeGrys VA. McColley SA, et al. Pediatr Pulmonol. 2020 Nov;55(11):3053-3056. doi: 10.1002/ppul.25027. Epub 2020 Aug 25. Pediatr Pulmonol. 2020. PMID: 32797669
We compared QNS sweat test rates in preterm (<37-weeks gestational age) vs term infants. We assessed age at sweat test and proportion of infants who did not have a sweat test reported by 60 days of age. ...
We compared QNS sweat test rates in preterm (<37-weeks gestational age) vs term infants. We assessed age at sweat test and proport …
Tolerance of 7% Hypertonic Saline in Pediatric Cystic Fibrosis Patients.
Talamo Guevara M, McColley SA, Rychlik K, Savant AP. Talamo Guevara M, et al. Among authors: mccolley sa. Pediatr Allergy Immunol Pulmonol. 2020 Jun;33(2):63-68. doi: 10.1089/ped.2019.1127. Pediatr Allergy Immunol Pulmonol. 2020. PMID: 35921579 Free PMC article.
Background: Clinical trials of 7% hypertonic saline (HTS) in cystic fibrosis (CF) show short- and long-term benefits, including improved pulmonary function and reduced exacerbation risk. ...
Background: Clinical trials of 7% hypertonic saline (HTS) in cystic fibrosis (CF) show short- and long-term benefits, including impro …
Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening.
Ren CL, Fink AK, Petren K, Borowitz DS, McColley SA, Sanders DB, Rosenfeld M, Marshall BC. Ren CL, et al. Among authors: mccolley sa. Pediatrics. 2015 Jun;135(6):e1386-92. doi: 10.1542/peds.2014-3698. Epub 2015 May 11. Pediatrics. 2015. PMID: 25963008
The goal of this study was to determine the prevalence, clinical features, and short-term outcomes of infants with CRMS. METHODS: We analyzed data from the US CF Foundation Patient Registry (CFFPR) from 2010 to 2012. ...
The goal of this study was to determine the prevalence, clinical features, and short-term outcomes of infants with CRMS. METHODS: We …
Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.
Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis; North American Scientific Advisory Group for ESCF. Schechter MS, et al. Among authors: mccolley sa. J Pediatr. 2009 Nov;155(5):634-9.e1-4. doi: 10.1016/j.jpeds.2009.04.059. Epub 2009 Jul 16. J Pediatr. 2009. PMID: 19608199 Free PMC article.
11 results